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SYSTEM AND METHODS FOR associated with significant complications , sometimes addi 
VENTILATION THROUGH A BODY CAVITY tional therapies are required such as the use of anticoagu 
lants ( heparin is standard ) . However , anticoagulants are 
CROSS REFERENCE TO RELATED often administered to the patient leading to additional 
APPLICATIONS 5 adverse side effects . Additionally , ECMO is expensive and 
complex to operate , limiting its accessibility for emergency 
This application claims the benefit of U . S . provisional care . 
applications 61 / 813 , 626 filed Apr . 18 , 2013 , which is incor Because of the high mortality rate , methods of bypassing 
porated by reference herein in its entirety . the lungs and delivering oxygen directly to the body have 
been explored for many years . Research has focused on FEDERAL FUNDING peritoneal oxygenation as a method of extrapulmonary res 
piration . The exchange of oxygen and carbon dioxide occurs This invention was made with government support under through the large surface area of the membrane that lines the grant number CBET1059726 awarded by the National Sci abdominal cavity , the peritoneum . ence Foundation . The government has certain rights in the 15 Previous methods include in situ extrapulmonary venti invention . lation ( EV ) . Success in oxygenating blood in situ has been 
FIELD OF THE INVENTION achieved by circulating fluorocarbons , blood , and liposome 
encapsulated hemoglobin ( a synthetic oxygen carrier ) 
The invention relates generally to the delivery of oxygen 20 through the intraperitoneal ( IP ) space , or cavity . Additional 
to a subject . More particularly , the invention relates to the previous methods include the study of carriers for the 
delivery of oxygen through a body cavity of a subject using delivery of oxygen . Carriers have included blood , perfluo 
oxygen microbubbles . rocarbon ( PFC ) , and synthetic hemoglobin carriers , for 
example TRM - 645 , which are effective . In contrast , pure 
BACKGROUND OF THE INVENTION 25 oxygen gas has been shown not to be an effective carrier . 
None of the effective carriers , however , are both safe and 
Oxygen is one of the basic essentials for sustaining life . economical . For example , PFCs are expensive to generate 
Today ' s medical technology can supply oxygen to patients and evaporate into potent greenhouse gases creating a sig 
experiencing pulmonary failure , otherwise known as respi - nificant environmental concern . They are also very stable , 
ratory failure . Pulmonary failure occurs when the lungs 30 tending to accumulate in biological systems in which they 
experience significant damage and are unable to supply the are used . Blood and products derived from blood ( like 
body and brain with oxygen . Pulmonary failure may be synthetic hemoglobin carriers ) suffer from scarcity and are 
caused by a variety of conditions including , for example , relatively expensive to fabricate and store . Furthermore , EV 
lung cancer , physical trauma , acute respiratory distress syn ventilation requires high volumes of perfusate ; therefore , a 
drome ( ARDS ) , aerosolized bioterrorism agents , and dis - 35 fluid that is economical and biodegradable is important . In 
eases such as severe acute respiratory syndrome ( SARS ) , additional , none of the previously developed methods have 
pneumonia , tuberculosis , sepsis , and other bacterial or viral achieved certain components for extrapulmonary respira 
infections , physical trauma , and chemical or smoke inhala - tion : ( 1 ) delivery of an adequate supply of oxygen , ( 2 ) 
tion . Currently , oxygen can be supplied to patients experi - long - term safety for the patient , and ( 3 ) cost - effectiveness . 
encing pulmonary failure through mechanical ventilation 40 Another form of therapy explored to deliver oxygen 
( MV ) or extracorporeal membrane oxygenation ( ECMO ) . systematically by circulating it through the IP space is a 
However , the mortality rate of patients receiving oxygen method that uses an oxygen microbubble ( OMB ) carrier . 
through MV or ECMO remains high . OMBs are oxygen filled bubbles that have a shell composed 
MV has been an ineffective method for delivering oxygen of a phospholipid monolayer . The phospholipid monolayer 
to the body in certain cases because oxygen exchange is 45 shell of an OMB has similar composition to lung surfactant 
decreased by damage to the lung and because of increased and requires comparable physical properties , such as rapid 
stress caused to the injured lung by the treatment . As an adsorption to and mechanical stabilization of the gas / liquid 
example , for patients experiencing severe hypoxemia arising interface and high gas permeability . Thus OMBs are also 
from lung injury MV may be inadequate owing to limited designed to mimic the mechanical and gas transport prop 
mass transfer in the injured lung ; over - inflation , barotrauma 50 erties of the alveolus to deliver the oxygen payload and 
and cyclic closing and reopening of the alveoli may further uptake carbon dioxide . 
damage the lung and trigger a pulmonary and systemic Previous research has focused on the delivery of OMBS 
inflammatory reaction that may lead to multiple system through intravenous ( IV ) oxygen delivery . However , IV 
organ failure . injection of OMBs is a one - way administration and does not 
ECMO is a temporary artificial extracorporeal support of 55 allow for the circulation of microbubbles into and out of the 
the respiratory system and / or cardiac system . ECMO was body to both deliver oxygen and remove carbon dioxide . 
first used in an adult in 1972 to treat severe respiratory Delivering oxygen using and IV appears to be a promising 
failure and in 1974 on the first newborn . Innovations in method for short - term rescue , but the prolonged continuous 
ECMO include the introduction of polymethylpentene hol - infusion of oxygen microbubbles into the bloodstream poses 
low fibers with non thrombogenic coatings and thin wire - 60 significant challenges for clinical translation , including the 
reinforced cannula walls . ECMO use has historically cen - potential for embolism , thrombosis , immunogenicity and 
tered on neonatal care . However , ECMO is an expensive toxicities of lipid and saline load . For example , with IV 
alternative therapy with limited availability in hospitals and injection of OMBs , any oxygen inspired through the lungs 
length of treatment . ECMO is able to bypass the injured can be absorbed by the microbubbles and can cause long 
lungs to deliver oxygen and allow the lungs to heal , however 65 circulating bubbles that may cause embolism or other prob 
there is a high risk of thrombosis and contamination of the lematic conditions , such as those observed in decompression 
blood because it is removed from the body . Since ECMO is sickness . Further , with the potential for embolism , IV injec 
stem 
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tion of microbubbles requires a strict upper limit on the lung injury , respiratory distress , cardiac arrest , or other 
microbubble size ( < 10 micrometers ) and on the microbubble situations in which lung function is sub - optimal . The inven 
volume fraction ( < 70 % ) . tion also precludes the need for an extracorporeal loop , thus Still another problem with IV injection of OMBs is that potentially circumventing the complications of thrombosis 
any nitrogen inspired through the lungs , such as that found 5 and immune reaction presented by the artificial surfaces 
in air , will be absorbed by the microbubbles . Thus , the exposed by ECMO . The prospect of providing a bridge to , 
microbubbles will exchange oxygen for nitrogen . The nitro or even supplanting ECMO , may significantly reduce the 
gen - containing microbubbles will be persistent , which can cost and complexity of EV . 
lead to serious problems , such as those observed during The ability to deliver oxygen via a body cavity may also 
decompression sickness and embolism ( thus leading to 10 have significant clinical implications . For example , acute 
severe morbidity and death ) . In addition , intravenous oxy - severe hypoxia of any origin ( due to airway obstruction or 
genation using OMBs cannot support long - term ventilation due to other causes ) results in irreversible brain injury within 
due to the lipid and saline load from continuous infusion . minutes . Administration of readily accessible oxygen - bear 
A demand therefore exists for a system and method for ing microbubbles may prevent the morbidity and mortality 
delivery of oxygen to a subject that is more effective and 15 associated with acute hypoxia in many subjects such as 
efficient than the current systems and methods presently human subjects . In addition , subjects suffering from lung 
available . The invention satisfies this demand . injury , which represent a significant percentage of those 
requiring intensive care , may benefit from the delivery of 
SUMMARY OF THE INVENTION oxygen that offers minimally invasive extrapulmonary oxy 
20 gen supplementation . Thus , ventilator - induced lung injury 
The invention is a system and methods that circulates may be minimized while avoiding critical hypoxia . Increas 
oxygen microbubbles ( OMBs ) through a body cavity . ing systemic oxygen saturations may improve hypoxic pul 
Although the invention is discussed in reference to the monary vasoconstriction and reduce pulmonary vascular 
intraperitorneal ( IP ) cavity , the invention is also applicable resistance in subjects with acute exacerbations of pulmonary 
to other cavities of the subject such as the gastrointestinal 25 hypertension . Infants , for example , born with cyanotic con 
( GI ) , pleural , cranial , vertebral , pericardial and other cavities genital heart disease , could benefit from an effective delivery 
as more fully described below . The invention delivers OMBS of oxygen that may lessen their hypoxemia preoperatively , 
to the body via circulation through a body cavity using an as well as during the early postoperative recovery period . 
oxygen carrier and perfusion apparatus to provide for safe This therapy could also provide care for cases of irreversible 
and effective ventilation . 30 pulmonary failure and , hence , act as a bridge to lung 
According to the invention , OMBs are designed for high transplant . This work may be translated to a medical thera 
oxygen carrying capacity , high oxygen delivery rate and peutic device with the aim of replacing or augmenting 
sufficient stability for storage and transport . Direct systemic ECMO with a less - invasive method of ventilation . 
oxygenation by injecting OMBs into the peritoneal space is According to the invention , OMBs are injected into a 
a radical change from existing oxygen delivery platforms . 35 body cavity and allowed some time to deliver oxygen and 
The procedure and apparatus for circulating OMBs through absorb carbon dioxide , followed by a saline flush to remove 
the peritoneal cavity is simple and straightforward , and the them from the cavity , followed by another injection of 
therapy precludes the need for an extracorporeal loop to OMBs into the cavity . This process cycle is repeated as 
circulate blood , thus potentially circumventing the compli - necessary . In the alternative , OMBs may be continuously 
cations from thrombosis and intracranial hemorrhage pre - 40 circulated through the cavity to release oxygen and absorb 
sented by ECMO . carbon dioxide and other gases . 
Circulating OMBs through a body cavity requires less Since blood is oxygenated by OMBs administered 
equipment and technical expertise than initiating and main - through the body cavity , the infusion of OMBs directly into 
taining an ECMO circuit . Thus , body cavity ventilation circulation is avoided . In addition , the upper size limit 
using OMBs may provide extrapulmonary ventilation ( EV ) 45 ( about 10 um diameter ) is not required to avoid vascular 
therapy to medical facilities that presently lack the funding occlusion . In certain embodiments , larger microbubbles 
or highly trained personnel required for operating an ECMO ( about 10 - 25 um diameter ) can be perfused through the body 
system . cavity without fear of occlusion because they are separated 
By circulating OMBs in the body cavity , oxygen and by gas - permeable membranous tissue from the intravascular 
carbon dioxide exchange occurs across the peritoneum , the 50 space . Thus , the effects of larger microbubble size distribu 
membrane of the abdominal cavity . Additionally , unlike IV tions on microbubble suspension viscosity and oxygen 
injection of microbubbles which cannot remove carbon release rate ( at equivalent volume fraction ) may be mea 
dioxide , a body cavity injection and circulation of OMBS sured . According to the invention , microbubbles may be 
according to the invention can beneficially remove carbon between 1 - 25 um in diameter with larger microbubbles 
dioxide . Additionally , the IP injection of OMBs , for 55 being about 9 - 21 um in diameter and smaller microbubbles 
example , is not subject to a strict upper limit of the being about 1 - 8 um in diameter . However , it is contemplated 
microbubble size and volume fraction since the that microbubbles may be between 1 - 100 um in diameter 
microbubbles are injected into the IP space ( not the vascu and even between 1 - 500 um in diameter . In addition , mix 
lature ) and can thus easily be removed . This provides tures of microbubbles may comprise microbubbles of dif 
oxygen to a subject , for example after it experiences a right 60 ferent sizes . The sizes of the OMBs contained within any 
pneumothorax . This significantly extends life in a subject one mixture may be only smaller microbubbles , only larger 
with an acute lung injury hypoxemia or similar situation in microbubbles or a combination of both smaller and larger 
which the lung function is sub - optimal . microbubbles . 
Direct systemic ventilation by circulating OMBs through In embodiments in which a perfusate is administered , the 
the body cavity space is a radical change from existing 65 perfusate may be about 60 % , 65 % , 70 % , 75 % , 80 % , 85 % , 
oxygen delivery platforms . For example , the invention may 90 % , or 95 % . In certain other example embodiments , the 
be used to supplement ventilation in cases of airway failure , OMB perfusate may be between 10 % - 90 % . 
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One advantage of the invention over previously devel - a supply device 106 through the subject ' s body cavity 104 
oped methods for extrapulmonary respiration is that the by a pump device 108 . As OMBs from the supply device 106 
invention delivers an adequate supply of oxygen , provides are pumped into the body cavity 104 of the subject 102 , 
long - term safety for the subject , and is cost - effective . waste is simultaneously removed from the subject and 
One advantage of the invention is that problems associ - 5 dispensed to the waste receptacle 110 . The monitoring of 
ated with ECMO are addressed and have the potential to several life sustaining data is performed with sensors 112 
significantly increase survivability of reversible pulmonary connected to the subject 102 and the monitoring device 114 . 
failure caused by pathologies and dysfunctions such as heart Data include , for example , intra - abdominal pressure . The 
disease , chronic lower respiratory disease , accidents , influ intra - abdominal pressure is measured to avoid high internal 
enza and pneumonia , airway failure , lung injury , respiratory 10 pressures that could damage the body ' s internal organs . 
distress syndrome , and other causes . In addition , the inven Other data that may also be monitored include blood gas 
tion may help subjects survive avian flu and severe acute levels of oxygen and carbon dioxide , heart pulse , blood 
respiratory syndrome ( SARS ) . pressure , heart ejection faction and similar cardiac data . The Other advantages of the invention include : reduced monitoring device 114 transmits the data to a computer thrombogenic and immunogenic effects owing to lack of 15 
direct contact with blood , reduced risk of embolism by the device 116 where the data is processed , for example , tabu 
OMBs or their lipid remnants because they are not in lated into a database , analyzed , and / or used to provide 
circulation , and the possibility of an input / output line to feedback to the supply device 106 , for example to adjust the 
remove carbon dioxide in addition to providing oxygen . amount of OMB delivered to the subject 102 . It is also 
An additional advantage of the invention is stability of the 20 contemplated that the supply device 106 transmits informa 
OMBs . OMBs are stable at high volume fractions > 90 % ) tion to the computer device 116 for processing , for example , 
for several weeks in refrigerated storage . to adjust the data the sensors 112 monitor . 
Another advantage is that OMBs administered intrave FIG . 2 illustrates an example embodiment of a supply 
nously ( < 70 vol % ) possess a rapid dissolving property and device 200 according to the invention . The supply device 
release of oxygen in the presence of oxygen - deficient media 25 200 includes a reaction chamber 202 with inlets for a lipid 
in vitro . solution 204 , and oxygen gas 206 . The lipid solution 204 and 
Additionally , OMBs according to the invention assist in oxygen gas 206 are mixed to create a mixture 207 , which is 
further sustaining life during 15 minutes of complete tra then cooled . The mixture 207 is cooled using material such 
cheal occlusion in vivo . Thus , OMBs are a promising as air or liquid passing through an inlet 208 and outlet 210 . 
platform for non - extracorporeal oxygen delivery . 30 In this process , a mix 212 of microbubbles and foam is 
These and other features , aspects , and advantages of the created . The microbubbles and foam mix 212 is passed to a 
invention will become better understood with regard to the collection container 220 . A solution 214 , such as saline , is 
following description , appended claims , and accompanying purged into the collection container 220 to combine with the 
microbubbles and foam mix 212 . The collection container 
220 includes a vent 216 for the discharge of gas . As the 
BRIEF DESCRIPTION OF THE DRAWINGS microbubbles and foam mix 212 combine with solution 214 , 
ambient gas is vented 216 and the foam 218 separates from 
FIG . 1 illustrates an example embodiment of the ventila the microbubbles 219 . The microbubbles 219 are then 
tion system according to the invention . collected in a syringe 222 , centrifuged and stored for future 
FIG . 2 illustrates an example embodiment of a supply 40 use . 
device according to the invention . FIG . 3 illustrates one embodiment of a ventilation system 
FIG . 3 illustrates one embodiment of a ventilation system 300 used in the delivery of oxygen to a subject according to 
used in the delivery of oxygen to a subject according to the the invention . In this example embodiment , a subject 301 
invention . has a right pneumothorax 302 . Cardiac arrest eventually 
FIG . 4 illustrates another embodiment of a ventilation 45 follows a right pneumothorax and is caused by lack of blood 
system used in the delivery of oxygen to a subject according oxygen ( hypoxemia ) and by elevated carbon dioxide levels 
to the invention . and subsequent low blood pH ( acidosis ) that result from 
FIG . 5 illustrates an exemplary computer system accord - pulmonary failure . To keep the subject alive longer while 
ing to the invention . life - saving treatment can be administered , the ventilation 
FIG . 6 illustrates an embodiment of the control scheme to 50 system 300 according to the invention is employed . A small 
monitor the perfusion of OMBs during delivery of oxygen to incision is made into the abdomen of the subject 301 to give 
a subject according to the invention . access to the IP cavity . Oxygen microbubbles from the 
FIG . 7 illustrates a graph of survival rates over time for supply device 304 are circulated into the IP cavity though a 
test subjects with a pneumothorax model and intraperitoneal supply tube 308 with a peristaltic pump 306 . Additionally a 
injection of oxygen microbubbles compared to saline injec - 55 scavenge tube 310 is used to remove fluid waste 312 , which 
tion according to the invention . may be controlled by a valve 314 . 
FIG . 8 illustrates a graph of survival rates over time for The effectiveness of IP extrapulmonary respiration is 
test subjects with an asphyxiation model and pleural injec established by measuring and monitoring several life sus 
tion of oxygen microbubbles compared to saline injection taining data . Intra - abdominal pressure may be measured at 
according to the invention . 60 the supply tube 308 inlet . This is measured to avoid high 
internal pressures that could damage the body ' s internal 
DETAILED DESCRIPTION OF EXAMPLE organs . The blood gas levels of oxygen and carbon dioxide , 
EMBODIMENTS heart pulse , blood pressure , heart ejection faction . Similar 
cardiac data may be measured with a paw cuff pulse 316 or 
FIG . 1 illustrates an example embodiment of the ventila - 65 similar medical device and perform periodic blood draws . 
tion system 100 . In this example embodiment , a subject 102 Additionally drug dosage in the blood may be measured 
is treated with oxygen microbubbles ( OMB ) dispensed from through a catheter 318 . Measuring and monitoring these and 
drawings . 
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other life sustaining data may be performed with a moni - for example , a modem , a network interface ( such as an 
toring device 320 and viewed on a monitor of a computer Ethernet card or Ethernet cable ) , a communication port , a 
device 322 . PCMCIA slot and card , wired or wireless systems ( such as 
In an alternate embodiment , ventilation is performed Wi - Fi , Bluetooth , Infrared ) , local area networks , wide area 
through the gastrointestinal ( GI ) space . The system setup for 5 networks , intranets , etc . 
perfusing the GI is identical to that shown in FIG . 3 with the It is contemplated that the main memory 508 , secondary 
exception that the small intestine is resected at the duode memory 510 , communication interface 516 , or a combina 
num and distal ileum with the mesentery left intact . The tion thereof , function as a computer usable storage medium , 
supply tube is inserted into the resected duodenum , the otherwise referred to as a computer readable storage 
scavenge tube is inserted into the resected distal ileum , and 10 medium , to store and / or access computer software including 
microbubbles from the supply device are pumped into and 
through the entire length of the small bowel . computer instructions . Certain embodiments of a computer 
readable storage medium do not include any transitory FIG . 4 illustrates another embodiment of a ventilation 
system 400 used in the delivery of oxygen to a subject signals or waves . For example , computer programs or other 
according to the invention . In this example embodiment , a 15 instructions may be loaded into the computer device 500 
subject 402 is connected to the system 400 through its such as through a removable storage device , for example , a 
pleural cavity 404 with an inlet / outlet tube 406 . The inlet / floppy disk , ZIP disks , magnetic tape , portable flash drive , 
outlet tube 406 allows the subject 402 to receive oxygen optical disk such as a CD or DVD or Blu - ray , Micro - Electro 
microbubbles from a supply device 410 through a pump 412 . Mechanical Systems ( MEMS ) , nanotechnological system . 
The microbubbles are warmed using fluid warmer device 20 Specifically , computer software including computer instruc 
414 . tions may be transferred from the removable storage unit 
The supply device 410 includes an oxygen tank 416 514 or hard disc unit 512 to the secondary memory 510 or 
connected to an oxygen inlet 418 that prevents the supply through the communication infrastructure 504 to the main 
device 410 from pressurizing while OMBs are pumped into memory 508 of the computer device 500 . 
the subject 402 . There is additionally an oxygen vent 420 to 25 Communication interface 516 allows software , instruc 
assist in maintain ambient pressure in the supply device 410 . tions and data to be transferred between the computer device 
The inlet / outlet tube 406 additionally allows for an expul - 500 and external devices or external networks . Software , 
sion of waste from the subject 402 from the pleural cavity instructions , and / or data transferred by the communication 
404 . The expulsion of waste may be controlled by a solenoid interface 516 are typically in the form of signals that may be 
valve 422 , which allows the waste to drain into a waste 30 electronic , electromagnetic , optical or other signals capable 
receptacle 424 . As this procedure of OMB injection is of being sent and received by the communication interface 
occurring , the subject ' s vital data is monitored with a 516 . Signals may be sent and received using wire or cable , 
number of health sensors 426 that are connected to a fiber optics , a phone line , a cellular phone link , a Radio 
monitoring device 428 . Additionally , pressure may be moni - Frequency ( RF ) link , wireless link , or other communication 
tored by a pressure sensor 430 . Health sensors 426 and 35 channels . 
pressure sensor 430 may be connected to a computer device Computer programs , when executed , enable the computer 
432 that may tabulate the data into a database , analyze the device 500 , particularly the processor 506 , to implement the 
data , and / or used the data to provide feedback to one or more methods of the invention according to computer software 
parts of the system 400 . As an example , the machine including instructions . 
computer device 432 may be connected to the supply device 40 The computer device 500 described herein may perform 
410 to monitor and / or automate the injection time or quan - any one of , or any combination of , the steps of any of the 
tity of OMBs . methods presented herein . It is also contemplated that the 
FIG . 5 illustrates an exemplary computer device 500 that methods according to the invention may be performed 
may be used to implement the methods according to the automatically , or may be invoked by some form of manual 
invention . One or more computer systems 500 may carry out 45 intervention . 
the methods presented herein as computer code . Computer The computer device 500 of FIG . 5 is provided only for 
device 500 includes an input / output display interface 502 purposes of illustration , such that the invention is not limited 
connected to communication infrastructure 504 — such as a to this specific embodiment . It is appreciated that a person 
bus — that forwards data such as graphics , text , and infor - skilled in the relevant art knows how to program and 
mation , from the communication infrastructure 504 or from 50 implement the invention using any computer system . 
a frame buffer ( not shown ) to other components of the The computer device 500 may be a handheld device and 
computer device 500 . The input / output display interface 502 include any small - sized computer device including , for 
may be , for example , a keyboard , touch screen , joystick , example , a personal digital assistant ( PDA ) , smart hand - held 
trackball , mouse , monitor , speaker , printer , Google Glass® computing device , cellular telephone , or a laptop or netbook 
unit , web camera , any other computer peripheral device , or 55 computer , hand held console or MP3 player , tablet , or 
any combination thereof , capable of entering and / or viewing similar hand held computer device , such as an iPad® , iPad 
data . Touch® or iPhone® . 
Computer device 500 includes one or more processors FIG . 6 is an example embodiment of the control system 
506 , which may be a special purpose or a general - purpose schematic that may be implemented at the solenoid valve to 
digital signal processor configured to process certain infor - 60 control the cavity pressure between the subject and the waste 
mation . Computer device 500 also includes a main memory receptacle . Through monitoring the cavity pressure , the 
508 , for example random access memory ( RAM ) , read - only solenoid valve may be opened to relieve and lower pressure 
memory ( ROM ) , mass storage device , or any combination within the cavity or may be closed to increase pressure 
thereof . Computer device 500 may also include a secondary within the cavity . The opening and closing of the valve may 
memory 510 such as a hard disk unit 512 , a removable 65 be automated with use of the control system implemented to 
storage unit 514 , or any combination thereof . Computer the computer device or may be manual with the control 
device 500 may also include a communication interface 516 , system providing an alarm . 
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Examples determine the oxygen - release rate ( ng / s ) . The oxygen - re 
lease rate is compared for microbubbles of two different size 
OMB Production : distributions ( 1 - 10 um diameter vs . 10 - 20 um diameter ) , 
In an example embodiment , lipids are mixed at a 9 : 1 each at three different OMB flow rates ( 1 , 10 and 20 
molar ratio of distearoyl phosphatidylcholine ( DSPC ) to 5 mL / min ) and three different volume fractions ( 50 , 70 and 
poly ( ethylene glycol ) - 40 stearate ( PEG40S ) in saline and 90 % ) . 
sonicated at low power to create the small , unilamellar IP Ventilation of Rat Model In Vivo : 
liposomes . O , and liposomes ( 5 mg / mL ) are then combined Using the system according to the invention , rats expe 
in the reaction chamber , where a high - power , 1 / 2 - inch diam - rienced a right pneumothorax after generally anesthetized by 
eter , 20 - kHz sonicator tip emulsifies the oxygen gas into 10 isoflurane ( 5 % induction to effect ) followed by sodium 
micrometer - scale spheres around which phospholipid pentobarbital ( 50 mg / kg , intramuscular ) . Anesthesia depth is 
adsorbs from vesicles and micelles and self - assembles into monitored and OMB perfusate is pumped into the IP space 
a highly condensed ( solid ) monolayer coating . OMBs are through a small incision in an upper quadrant of the abdo 
separated from macroscopic foam in a subsequent flotation men . The IP incision is sutured / glued around the supply and 
container and collected in syringes and centrifuged ( 500 g 15 scavenger tubing to form a seal . Intra - abdominal pressure is 
for 3 min ) to form concentrated OMBs . The sonication maintained at 8 mmHg through the use of a fluidic control 
chamber and container are jacketed with circulating coolant solenoid valve and pressure catheter at the scavenger tube 
to maintain a constant temperature of 20° C . exit . Intra - abdominal pressure of 8 mmHg is used because it 
OMBs are fabricated for live animal testing , in which four is typical of human insufflation pressures during laparo 
factors are investigated : perfusate , perfusion rate , motility 20 scopic surgery . Cardiac arrest will eventually follow pneu 
drug , and method ( IP or GI ) . OMB perfusate at 70 % and mothorax and is caused by lack of blood oxygen ( hypox 
90 % indicate the volume fraction of oxygen in the OMB emia ) and by elevated carbon dioxide levels and subsequent 
emulsion . At 70 % , the OMB emulsion ' s rheological prop low blood pH ( acidosis ) , which result from pulmonary 
erties are similar to saline and the perfusate is expected to failure . The effectiveness of IP EV is established from 
circulate well through the IP space . 25 periodic tail - vein blood draws ( 5 - minute intervals , total 
OMB Size Distribution Measurements : draws less than 1 % body weight ) and measurement of blood 
OMB size distribution is varied by choosing different oxygen , carbon dioxide , pH , osmolality levels , and general 
residence times in the flotation container ( e . g . , 153 min for blood chemistry . 
a 10 - um diameter cut - off ; 38 min for a 20 - um diameter Fluids used as a perfusate are saline as a control or a 
cut - off ) . Size distribution is measured , for example , by 30 solution with an OMB concentration of 70 % or 90 % and 
electrical capacitance , light extinction / scattering , flow dispensed at fluid flow rates of 0 , 8 , and 16 mL / min . OMB 
cytometry scatter , and optical microscopy . Alternatively , perfusate at 70 % and 90 % indicate the volume fraction of 
size selection may be unnecessary and may be removed oxygen in the OMB emulsion . At 50 % , the OMB emulsion ' s 
from the process . OMB volume fraction is measured , for rheological properties are similar to saline . In certain other 
example , by gravimetric analysis and varied from 50 - 90 vol 35 example embodiments , an OMB concentration between 
% by dilution with saline . Microbubble size and concentra - 60 % - 95 % may be used . In certain other example embodi 
tion is measured over time to investigate coalescence , Ost ments , an OMB concentration of about 10 % - 90 % may be 
wald ripening and stability in storage . used . At 90 % volume fraction , the OMBs ability to circulate 
OMB Dissolution in Oxygen - Depleted Media : in the IP space degrades due to increased viscosity , but 
Clinical translation of OMB technology to treat hypox - 40 oxygen content is enhanced . It was calculated that perfusing 
emia requires quantitative modeling of the pharmacokinetics OMBs at 8 mL / min provides sufficient oxygen capacity for 
of oxygen delivery , whether administered through the IV , IP a 400 g rat . Perfusing OMBs at 8 mL min - 1 provides 
or GI route . A model for single OMB dissolution in an sufficient oxygen capacity considering a 400 g rat . Perfusion 
oxygen - depleted medium with the presence of venous gases at a higher rate ( 16 mL min - - ) and introducing a stagnant 
( 30 mmHg 0 , 600 mmHg N , and 50 mmHg CO ) has been 45 OMB bolus ( 0 mL min ) . The motility enhancing drug 
developed . Results demonstrate the microbubble exhibits ghrelin is administered ( 200 mg kg - dose ) in half of the 
two dissolution regimes . First , rapid dissolution occurs as 02 tests via the tail vein catheter 30 minutes prior to anesthe 
dissolves out , even as N , and CO , counter - diffuse into the tization . 
bubble . Second , 0 , is depleted and slower dissolution occurs IP Ventilation of Rabbit Model In Vivo : 
as N2 and CO2 dissolve out . For a 20 - um diameter 50 Male New Zealand White rabbits ( n = 13 , m = 2 . 260 + 0 . 196 
microbubble , most of the oxygen is released within 10 s . The kg ) were weighed and anesthetized by 5 % isoflurane gas by 
bubble then carries N , and CO2 ( therefore acting as a blood nose cone to effect . Rabbits were then intubated with an 
gas scrubber for non - oxygen species ) . endotracheal tube and laid in the supine position on a 
The simulation results indicate that the highest rate of warming pad set at 38° C . to maintain body temperature . The 
oxygen transfer for the suspension occurs with the minimal 55 abdomen of the rabbit was shaved , divided into quadrants 
OMB residence time in the IP space . Thus , rapid mixing with a marker , and sterilized . A veterinary monitor was used 
should provide high mass transfer coefficients for both OMB to monitor and record vitals via two sensors placed rectally ; 
oxygen release and oxygen transfer in the fluid medium to a pulse oximetry sensor was used to measure pulse rate and 
the parietal peritoneum and visceral peritoneum membranes . arterial oxygen hemoglobin saturation ( SpO2 ) , and a tem 
The results also indicate that oxygen - release rate increases 60 perature probe was used for measuring body temperature . 
substantially for larger microbubbles . It is expected that The rabbit was given an intramuscular injection of ket 
mixing conditions ( i . e . , viscosity ) will dominate the rate of amine - xylazine ( 35 - 5 mg / kg ) and then gradually weaned off 
oxygen release . isoflurane and allowed to breathe room air . A small incision 
Oxygen - Release Rate Measurements : was made into the abdomen to allow access for placement of 
Three trials ( three measurements per trial ) are taken for 65 infusion and drainage tubing ( 3 . 2 mm inner , 4 . 8 mm outer 
each OMB flow rate and size distribution . Oxygen content diameter , Tygon ) in the intraperitoneal cavity and then 
is plotted versus time , and the linear regime is used to sutured closed . A 12 G indwelling catheter and a 14 G needle 
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connected to pressure transducers were inserted into the IP s haved , divided into quadrants with a marker , and sterilized . 
cavity for measuring intra - abdominal pressure via a data A veterinary monitor was used to monitor and record vitals 
acquisition and custom control system . The control system via two sensors placed rectally ; a pulse oximetry sensor was 
was designed to use IA pressure and a solenoid fixed to the used to measure pulse rate and arterial oxygen hemoglobin 
drainage line to regulate the volume of perfusate adminis - 5 saturation ( Spo , ) , and a temperature probe was used for 
tered into the cavity . measuring body temperature . The rabbit was given an intra 
Perfusate was pumped through a fluid warmer set at 40 . 4° muscular injection of ketamine - xylazine ( 35 - 5 mg / kg ) and C . and into the IP space with a peristaltic pump at 80 mL / min then gradually weaned off isoflurane and allowed to breathe for 3 minutes and then at dose of 12 . 6 mL / min * kg thereafter . room air . A small incision was made into the abdomen to At this time , the endotracheal tube was hermetically sealed 10 allow access for placement of infusion and drainage tubing to prevent oxygen intake and simulate complete lung failure . ( 3 . 2 mm inner , 4 . 8 mm outer diameter , Tygon ) in the pleural The fluids used as a perfusate were oxygenated saline for the cavity and then sutured closed . A 12 G indwelling catheter control group and OMBs for the experimental group . The 
survival data for rabbits using saline survived 6 . 9 + 0 . 6 min and a 14 G needle connected to pressure transducers were 
utes . The OMB treated rabbits survived on average for 18 15 inserted into the pleural cavity for measuring pressure via a 
minutes and one outlier lived for 72 minutes after the trachea data acquisition and custom control system as shown in FIG . 
tube had been sealed : The outlier 72 minute survival time 6 . The control system was designed to use IA pressure and 
rabbit had successful circulation and IA pressure below 8 a solenoid fixed to the drainage line to regulate the volume 
mmHg . of perfusate administered into the cavity . 
GI Ventilation of Rat Model In Vivo : 20 Perfusate was pumped through a fluid warmer set at 40 . 4° 
The test setup for perfusing the GI is identical to that for C . and into the pleural space . At this time , the endotracheal 
perfusing the IP except that the small intestine is resected at tube was hermetically sealed to prevent oxygen intake and 
the duodenum and distal ileum ( with the mesentery left simulate complete lung failure . The fluids used as a per 
intact ) . The supply tube is inserted into the resected duode - fusate were oxygenated saline for the control group and 
num , the scavenge tube is inserted into the resected distal 25 OMBs for the experimental group . The survival data for 
ileum , and perfusate is pumped into and through the entire rabbits using saline under a saline bolus or saline perfusion 
length of the small bowel . Saline with neutral oxygen injection survived an average of seven minutes . The OMB 
tension with respect to atmosphere is used as a third per perfusion treated rabbits survived on average for 15 minutes 
fusate to provide a control for all experiments . Six rats are and OMB bolus treated rabbits survived on average for 17 . 5 
tested at the given OMB perfusion rate of 8 and 16 mL / min 30 minutes as shown in FIG . 8 . 
flow rates and the internal pressure over time was measured While the disclosure is susceptible to various modifica to find suitable conditions for infusion and scavenging . tions and alternative forms , specific exemplary embodi 
Results show that internal pressure never surpasses the re never surpasses the ments of the invention have been shown by way of example 
upper limit of 8 mmHg and the system perfuses saline at the in the drawings and have been described in detail . It should 
desired rates while maintaining physiological pressure lev - 35 be understood , however , that there is no intent to limit the 
els in the phantom abdomen . disclosure to the particular embodiments disclosed , but on 
Perfusing OMBs at 8 mL min - 1 in 400 g rats with a right the contrary , the intention is to cover all modifications , 
pneumothorax survival rates are promising over time . FIG . equivalents , and alternatives falling within the scope of the 
7 illustrates a graph of survival rates over time for test disclosure as defined by the appended claims . 
subjects with a pneumothorax model and intraperitoneal 40 
injection of oxygen microbubbles compared to saline injec What is claimed is : 
tion according to the invention . The fluids used as perfusate 1 . A method for administering oxygen to a subject , 
were ( 1 ) saline as a control or ( 2 ) a solution with an OMB comprising the steps of : 
concentration of ~ 50 vol % . Intra - abdominal pressure was providing a supply device containing a reaction chamber ; 
measured at the supply tube inlet to avoid high internal 45 mixing in the reaction chamber a lipid solution received 
pressures that could damage internal organs or the IP cath from a first inlet of a supply device and an oxygen gas 
eter seal . Cardiac arrest eventually follows a right pneumo received from a second inlet of the supply device to 
thorax and is caused by lack of blood oxygen ( hypoxemia ) form a mixture ; 
and elevated carbon dioxide levels and subsequent low cooling the mixture using a cooling material passing 
blood pH ( acidosis ) , which result from pulmonary failure . 50 through the supply device from a third inlet to an outlet , 
As shown in FIG . 7 , saline control specimens survived for said cooling step creating in the reaction chamber a mix 
an average of ~ 14 . 1 minutes after right pneumothorax in the of a plurality of oxygen microbubbles and a foam ; 
presence of saline . In comparison , the specimen injected transporting the mix to a collection container ; 
with OMBs survived for an average of - 83 . 3 minutes after adding a saline solution to the collection container to 
right pneumothorax , which represents a ~ 8 - fold improve - 55 separate the plurality of oxygen microbubbles and the 
ment in survivability in comparison to the controls ( p < 0 . 5 ; foam ; 
Gehan - Breslow - Wilcoxon Test ) . The effectiveness of IP venting from the collection container a gas formed during 
ventilation was established by measuring saturated arterial said adding step ; 
oxygen fraction ( SAO2 ) . Results demonstrate that cardiac collecting the plurality of microbubbles into a syringe ; 
arrest in hypoxemic rodents is significantly delayed by 60 delivering by a pump device from the syringe one or more 
intraperitoneal administration of OMBs . oxygen microbubbles to a body cavity of the subject ; 
Pleural Cavity Ventilation of Rabbit Model In Vivo : monitoring by a monitoring device including one or more 
Male New Zealand White rabbits were weighed and sensors data resultant from delivery of the one or more 
anesthetized by 5 % isoflurane gas by nose cone to effect . oxygen microbubbles to the body cavity ; 
Rabbits were then intubated with an endotracheal tube and 65 receiving by a computer device the data ; and 
laid in the supine position on a warming pad set at 38° C . to processing the data by the computer device to measure 
maintain body temperature . The abdomen of the rabbit was effectiveness of extrapulmonary respiration . 
tact 
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2 . The method for administering oxygen to a subject 
according to claim 1 further comprising the step of receiving 
by a waste receptacle waste from the subject . 
3 . The method for administering oxygen to a subject 
according to claim 1 , wherein the data includes one or more 5 
of the following : intra - abdominal pressure , blood gas levels 
of oxygen , blood gas levels of carbon dioxide , heart pulse , 
blood pressure , and heart ejection faction . 
4 . The method for administering oxygen to a subject 
according to claim 1 further comprising the step of using by 10 
the computer device the processed data to adjust the delivery 
of the one or more oxygen microbubbles to the subject . 
5 . The method for administering oxygen to a subject 
according to claim 1 , wherein the one or more oxygen 
microbubbles comprise a shell composed of a phospholipid 15 
monolayer . 
6 . The method for administering oxygen to a subject 
according to claim 1 , wherein each microbubble is 10 - 25 
micrometers ( um ) in diameter . 
7 . The method for administering oxygen to a subject 20 
according to claim 1 , wherein each microbubble is 1 - 8 
micrometers ( um ) in diameter . 8 . The method for administering oxygen to a subject 
according to claim 1 , wherein the body cavity of the subject 
of the delivery step includes one or more of the following 25 
cavities : intraperitoneal , gastrointestinal , pleural , cranial , 
vertebral , and pericardial . 
